Pancreatic Cancer Case Control Association Study

Pancreatic cancer is the fourth leading cause of cancer death in the United States. This is in large part due to the rapidly fatal course of this disease, as the vast majority of patients die within months of diagnosis and the five-year survival rate is less than 5. We have brought together over 8000 participants from 9 studies of pancreatic cancer, to conduct a GWAS of pancreatic cancer. The studies were drawn from the Pancreatic Cancer Case-Control consortium and include case-control studies from the United States, Europe and Australia. Sites include: Johns Hopkins National Familial Pancreas Tumor Registry, Mayo Clinic Biospecimen Resource for Pancreas Research, Ontario Pancreas Cancer Study (OPCS), Yale University, MD Anderson Case Control Study, Queensland Pancreatic Cancer Study, University of California San Francisco Molecular Epidemiology of Pancreatic Cancer Study, International Agency of Cancer Research and Memorial Sloan Kettering Cancer Center.]]>
Genome-wide association study of individuals with primary pancreatic adenocarcinomas and matched controls. 3,933 cases and 3,651 controls were genotyped on the HumanOmniExpressExome-8v1 arrayInclusion Criteria:Individuals with a primary pancreatic adenocarcinomas (ICD-O-3 code C250-C259)Exclusion Criteria:Individuals with an endocrine pancreatic tumor (C25.4, histology codes: 8150, 8151, 8153, 8155, 8240)]]>